India Plans To End Dependence On China Bulk Imports By 2020
This article was originally published in PharmAsia News
Executive Summary
India says it is aiming to end its dependence on Chinese bulk drug imports by 2020 as it announces plans to set up a string of pharmaceutical industrial parks to boost manufacturing capacity.
You may also be interested in...
Sanofi API Unit Expects $1bn Sales By 2022
Sanofi has announced plans to create the world’s second-largest API manufacturer to help ease European drugmakers’ dependence on supplies of raw materials from China and India.
Share Fillip As Indian Pharma Crests US Regulatory Hump
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.
Biocon, Quark Win Pioneering Indian Nod For RNAi Eye Therapy Trial
Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.